Arthrogryposis multiplex congenita due to congenital myasthenic syndrome

J Vajsar1, A Sloane, D L MacGregor

  • 1Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.

Pediatric Neurology
|April 1, 1995
PubMed

Insights

Congenital myasthenic syndrome in infants can cause severe weakness and developmental delay. Early diagnosis and pyridostigmine treatment can significantly improve muscle function and clinical outcomes.

Area of Science:

  • Neurology
  • Pediatrics
  • Genetics

Background:

  • Congenital myasthenic syndrome (CMS) is a group of inherited disorders affecting neuromuscular transmission.
  • It can manifest in neonates with severe hypotonia, ptosis, and respiratory distress, leading to developmental delays.

Observation:

  • Two neonates presented with hypotonia, contractures, ptosis, extraocular weakness, bulbar symptoms, and respiratory distress.
  • Standard electrodiagnostic tests and acetylcholine receptor antibodies were normal, but single-fiber EMG showed prolonged jitter.
  • Muscle biopsies revealed motor endplate abnormalities, including synaptic cleft flattening and reduced branching.

Findings:

  • The patients were diagnosed with arthrogryposis multiplex congenita secondary to congenital myasthenic syndrome.
  • Electron microscopy identified postsynaptic abnormalities at the neuromuscular junction.
  • Clinical improvement was observed with pyridostigmine therapy, indicating efficacy of anticholinesterase treatment.

Implications:

  • This case highlights the importance of considering CMS in neonates with unexplained neuromuscular symptoms, even with normal initial tests.
  • Electrophysiological and pathological findings are crucial for diagnosing CMS, particularly when acetylcholine receptor antibodies are absent.
  • Anticholinesterase therapy offers a potential treatment pathway for improving outcomes in affected children.

Related Concept Videos

Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...